[Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II]

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare genetic disorder.
• Early diagnosis and intervention are crucial for managing MPS II and improving patient outcomes.
• Enzyme replacement therapy (ERT) is a key treatment modality for MPS II.

Observation:

• A male infant diagnosed with MPS II within the first month of life due to a family history of severe disease.
• Initiation of Elaprase (idursulfase) ERT at two months of age.
• Ten years of continuous ERT with Elaprase.

Findings:

• The patient exhibited normal physical and mental development over the 10-year treatment period.
• The only observed clinical manifestations were a relatively large head circumference (+2.1 SD) and mild joint mobility reduction.
• The treatment successfully attenuated the expected severe disease progression of MPS II.

Implications:

• Early initiation of ERT for MPS II can significantly mitigate disease severity and improve long-term developmental outcomes.
• This case highlights the potential of proactive therapeutic strategies in managing rare genetic lysosomal storage disorders.
• Further research into the long-term efficacy and optimal timing of ERT in MPS II is warranted.